Abstract
There are currently 25 new clinical cellular therapy trials in progress for cardiovascular disease in the US, and a similar number ongoing in Europe. The lack of standardization in cell isolation, preparation, storage, and time and localization of delivery, present clear hurdles to this growing field. This emphasizes the need for an organized task force to work closely with the FDA to agree upon standardized methods with the end result being improvements in patient care and enhanced knowledge in the field.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 185-187 |
| Number of pages | 3 |
| Journal | Journal of cardiovascular translational research |
| Volume | 1 |
| Issue number | 3 |
| DOIs | |
| State | Published - Sep 2008 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Stem cell therapy trials: a call for standardization.'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS